Emcure Pharma IPO is a book built issue of Rs 1,952.03 crores. The issue is a combination of fresh issue of 0.79 crore shares aggregating to Rs 800.00 crores and offer for sale of 1.14 crore shares aggregating to Rs 1,152.03 crores.
Emcure Pharma IPO opens for subscription on July 3, 2024 and closes on July 5, 2024. The allotment for the Emcure Pharma IPO is expected to be finalized on Monday, July 8, 2024. Emcure Pharma IPO will list on BSE, NSE with tentative listing date fixed as Wednesday, July 10, 2024.
Emcure Pharma IPO price band is set at ₹960 to ₹1008 per share. The minimum lot size for an application is 14 Shares. The minimum amount of investment required by retail investors is ₹14,112. The minimum lot size investment for sNII is 15 lots (210 shares), amounting to ₹211,680, and for bNII, it is 71 lots (994 shares), amounting to ₹1,001,952.
Kotak Mahindra Capital Company Limited, Axis Capital Limited, J.P. Morgan India Private Limited and Jefferies India Private Limited are the book running lead managers of the Emcure Pharma IPO, while Link Intime India Private Ltd is the registrar for the issue.
Refer to Emcure Pharma IPO RHP for detailed information.
Emcure Pharma IPO Details
| IPO Date | July 3, 2024 to July 5, 2024 |
| Listing Date | [.] |
| Face Value | ₹10 per share |
| Price Band | ₹960 to ₹1008 per share |
| Lot Size | 14 Shares |
| Total Issue Size | 19,365,346 shares (aggregating up to ₹1,952.03 Cr) |
| Fresh Issue | 7,936,507 shares (aggregating up to ₹800.00 Cr) |
| Offer for Sale | 11,428,839 shares of ₹10 (aggregating up to ₹1,152.03 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
| Share holding pre issue | 180,852,116 |
| Share holding post issue | 188,788,623 |
Emcure Pharma IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 50% of the Net Issue |
| Retail Shares Offered | Not less than 35% of the Net Issue |
| NII (HNI) Shares Offered | Not more than 15% of the Net Issue |
Emcure Pharma IPO Timeline (Tentative Schedule)
Emcure Pharma IPO opens on July 3, 2024, and closes on July 5, 2024.
| IPO Open Date | Wednesday, July 3, 2024 |
| IPO Close Date | Friday, July 5, 2024 |
| Basis of Allotment | Monday, July 8, 2024 |
| Initiation of Refunds | Tuesday, July 9, 2024 |
| Credit of Shares to Demat | Tuesday, July 9, 2024 |
| Listing Date | Wednesday, July 10, 2024 |
| Cut-off time for UPI mandate confirmation | 5 PM on July 5, 2024 |
Emcure Pharma IPO Lot Size
Investors can bid for a minimum of 14 shares and in multiples thereof. The below table depicts the minimum and maximum investment by retail investors and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 14 | ₹14,112 |
| Retail (Max) | 14 | 196 | ₹197,568 |
| S-HNI (Min) | 15 | 210 | ₹211,680 |
| S-HNI (Max) | 70 | 980 | ₹987,840 |
| B-HNI (Min) | 71 | 994 | ₹1,001,952 |
| Lot Size Calculator | |||
Emcure Pharma IPO Promoter Holding
Satish Mehta and Sunil Mehta are the company promoters.
| Share Holding Pre Issue | 98.90% |
| Share Holding Post Issue |
About Emcure Pharmaceuticals Limited
Incorporated in 1981, Emcure Pharmaceuticals Limited, an Indian pharmaceutical company, develops, manufactures, and globally markets a wide range of pharmaceutical products across several major therapeutic areas.
The company has been ranked 13th in domestic sales among pharmaceutical companies in India for MAT September 2023 and 4th in market share in its covered markets for the same period. Additionally, it is the leading pharmaceutical company in gynaecology and HIV antiviral therapeutic areas for the MAT September 2023.
In the six months ended September 30, 2023, and the Financial Year 2023, sales in India contributed 50.84% and 53.16% of the company’s total revenue, respectively. The company’s Domestic sales grew at a CAGR of 10.80% between September 2019 and September 2023, outperforming the Indian pharmaceutical market.
As of September 30, 2023, Emcure Pharma employed 552 scientists and operated five research facilities in India. They filed over 1,800 documents globally, including 204 in the EU and 133 in Canada. They had 201 granted patents, 33 pending patent applications, and submitted 102 drug master files.
Emcure Pharmaceuticals has 13 manufacturing facilities in India. These facilities can produce various pharmaceutical and biopharmaceutical products, including pills, liquids, injectables, and complex ingredients such as chiral molecules, iron molecules, and cytotoxic substances.
As of September 30, 2023, the company’s marketing and distribution network in India was supported by over 5,000 field personnel who regularly interacted with healthcare providers. The distribution network included over 5,000 stockists, served by 37 carry-and-forward agents.
Emcure Pharmaceuticals Limited Financial Information (Restated Consolidated)
Emcure Pharmaceuticals Limited’s revenue increased by 11.33% and profit after tax (PAT) dropped by -6.1% between the financial year ending with March 31, 2024 and March 31, 2023.
| Period Ended | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
| Assets | 7,806.16 | 6,672.53 | 6,063.47 |
| Revenue | 6,715.24 | 6,031.72 | 5,918.86 |
| Profit After Tax | 527.58 | 561.85 | 702.56 |
| Net Worth | 2,952.28 | 2,501.13 | 1,987.55 |
| Reserves and Surplus | 2,722.40 | 2,293.77 | 1,791.03 |
| Total Borrowing | 2,091.94 | 2,202.42 | 2,102.19 |
| Amount in ₹ Crore | |||
Key Performance Indicator
The market capitalization of Emcure Pharma IPO is Rs 19029.89 Cr.
| KPI | Values |
|---|---|
| ROE | 16.90% |
| ROCE | 19.37% |
| Debt/Equity | 0.67 |
| RoNW | 16.87% |
| P/BV | 6.18 |
Check Emcure Pharma IPO Peer Comparison here.
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 29.17 | 27.95 |
| P/E (x) | 34.55 | 36.07 |
Note:
- The Pre IPO EPS is calculated based on Pre issue shareholding as on date of RHP and the latest FY earnings as of March 31, 2024 that is available in RHP.
- The Post Issue EPS is calculated based on the Post issue shareholding and annualized FY earnings of March 31, 2024 that is available in RHP.
Objects of the Issue (Emcure Pharma IPO Objectives)
The Company proposes to utilise the Net Proceeds towards funding the following objects:
- Repayment and/ or prepayment of all or a portion of certain outstanding borrowings availed by the company; and
- General corporate purposes
Emcure Pharma IPO Review (Apply)
[Dilip Davda] The company is one of the leading pharma company having niche products and serving global markets. It marked growth in its top lines, but bottom line posted declining trends due to higher interest and depreciation costs. Based on FY24 earnings, the issue appears fully priced. Reduction in debt post IPO will improved its bottom line commensurately. Investors may park funds for the medium to longer term. Read detail review…
Emcure Pharma IPO Prospectus
Emcure Pharmaceuticals Limited Contact Details
Emcure Pharmaceuticals Limited
Plot No. P-1 and P-2,
IT-BT Park, Phase II, M.I.D.C.,
Hinjawadi, Pune -411 057
Phone: +91 20 3507 0033
Email: investors@emcure.co.in
Website: https://www.emcure.com/
Emcure Pharma IPO Registrar
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: emcure.ipo@linkintime.co.in
Website: https://linkintime.co.in/initial_offer/public-issues.html